Cell-Free Protein Expression Market

Cell-Free Protein Expression Market Outlook (2024 to 2034)

The global cell-free protein expression market is all set to reach a value of US$ 374.5 million in 2024 and has been analyzed to further expand at a CAGR of 7.6% to end up at US$ 780.7 million by 2034.

In molecular biology, cell-free protein expression (CFPE) is one of the most widely used methods. CFPE allows for the creation of proteins in a matter of hours, while cell-based protein production typically requires several days to many weeks. As such, from the initial synthesis to the final application, CPSE-based protein manufacturing saves time as compared to traditional methods.

• For example, Promega's transcription and translation systems combine the process into a single tube format, reducing time compared to eukaryotic in vitro transcription.

Similarly, easy in vitro transcription and translation are facilitated by the human cell-free protein expression method. An hour is all that is needed to finish the protein expression single tube process. High-yield protein production and purification are made possible by this expression method.

Quicker production of required proteins in a short amount of time is made possible by cell-free expression kits.

• Utilizing template DNA, the AccuRapid CFPE kit facilitates the production of a necessary protein in a reaction tube in less than three hours. As a result, a shorter expression time is encouraging more sectors to use CFPE to produce proteins, which might propel the CFPE market in the future.

Systems for expressing proteins without cells are becoming essential tools for application in synthetic biology. Although several methods in synthetic biology rely on cell-based systems, their limitations have aided in the development of cell-free protein expression and its uses in synthetic biology.

Techniques without cells are being explored for prototyping and biomanufacturing. Cell-free systems are used in prototyping applications to evaluate and improve biosynthetic pathways before administration in living cells and subsequent scaling up.

Enzymatic pathways are built in a matter of days instead of months due to the modular assembly of lysates containing enzymes generated by CFPS instead of living cells. Testing for combination metabolic pathways can be expedited by using this strategy along with automation and machine learning.

• Commercial strains and plasmids, such as NEB Turbo and BL21 from New England Biolabs, are utilized in cell-free prototyping processes.

Report Attribute	Detail
Cell-Free Protein Expression Market Size (2024E)	US$ 374.5 Million
Forecasted Market Value (2034F)	US$ 780.7 Million
Global Market Growth Rate (2024 to 2034)	7.6% CAGR
Canada Market Growth Rate (2024 to 2034)	6.4% CAGR
China Market Value (2034F)	US$ 70 Million
North America Market Share (2024E)	48%
East Asia Market Share (2034F)	21.5%
Key Companies Profiled	Thermo Fisher Scientific, Inc.; Takara Bio Company; New England Biolabs; Promega Corporation; Jena Bioscience GmbH; GeneCopoeia, Inc.; Biotechrabbit GmbH; Cube Biotech GmbH; CellFree Sciences Co., Ltd.; Bioneer Corporation; Agilent Technologies Inc.; Bio-Rad Laboratories, Inc.; Genscript Biotech Corporation; Merck KGaA; Promega Corporation; Qiagen.

Which Factors are Generating Profitable Opportunities for Market Players?

“Research Initiatives in Isotopes and Amino Acids Changing Market Scenario”

The market is projected to provide players with a plethora of profitable prospects in the coming years. A few dominant businesses that produce kits for cell-free protein production have dominated the sector. Several novel applications have been developed as a result of strong research efforts in the field of cell-free protein synthesis.

Several developments in the cell-free protein expression system industry have facilitated new applications in the production of protein libraries for functional genomic investigations, tailored drug development, and the synthesis of virus-like particles, among many other uses, contributing to the expansion of the cell-free protein expression market size.

For example, cell-free protein production techniques make it simple to add isotope-labeled amino acids in a targeted and selective way, which helps protein NMR investigations achieve high resolution. Similar to this, in X-ray crystallography, the phase-contrast problem is resolved to identify protein structure by multi-wavelength anomalous diffraction (MAD) when cell-free protein expression is combined with protein-heavy metal derivatives like selenomethionine.

Membrane protein solubilization is one of the potential uses for cell-free protein expression systems in the future. Prokaryotic and wheat germ systems can contribute supplements directly to the reaction mixture in the form of nanodiscs, detergents, or liposomes; eukaryotic systems can use endogenous microsomes or proteoliposomes.

“Growing Usage of Microfluids and Focus on Tailored Drug Development”

One of the most significant and cutting-edge methods for studying protein expression is microfluidics, which is becoming more and more popular as a means of producing proteins heterologously, including antibodies, growth factors, nanobodies, and premium protein components for food. There's a growing need for productive production hosts.

Another cutting-edge technique for determining the phosphorylation and expression levels of various proteins at the single-cell level is the microfluidic antibody capture (MAC) chip. Technological developments in microfluidics have produced reliable methods for analyzing and assessing both cancerous and non-cancerous cells.

Creative and cutting-edge uses of microfluidics in the study of protein expression are expected to aid in overcoming difficulties associated with protein analysis; as a result, this technology is anticipated to have substantial development prospects.

What is Shrinking Opportunities for Cell-Free Protein Expression Providers?

“Limitations in Conducting Humanized Glycosylation Patterns”

Future expansion of the cell-free protein expression business is expected to be hindered by the absence of eukaryotic co- and post-translational modifications. One of its drawbacks is the incapacity of prokaryotic cell-free systems, including E. Coli and wheat germ extracts, to perform humanized glycosylation patterns.

A mammalian membrane protein, such as canine microsomal membranes, must be added to the translation mixture to create glycosylated proteins using rabbit reticulocyte systems; however, this can result in a lower total protein yield and higher costs. Its use at the industrial level in the absence of eukaryotic co- and post-translational modifications by affordable systems like E. coli may limit humanized R&D investigations.

The second factor limiting the expansion of the cell-free protein expression business is its high cost and short reaction time. Large-scale protein expression is typically impractical for cell-free systems since it can be a rather capital-intensive process requiring expensive reagents like phosphate compounds in nucleotide form and supplementary energy sources.

Because of their short reaction times, cell-free systems may be adversely affected by the process's addition of energy and substrate sources. One reason for the restricted capabilities of the resulting protein foldings is a short reaction scale. All of these factors are affecting cell-free protein expression market growth.

Country-wise Evaluation

The market in South Korea is forecasted to expand at a CAGR of 8% from 2024 to 2034. The country is expected to occupy a cell-free protein expression market share of 24.3% in East Asia by the end of 2034.

What are the Factors Supporting Cell-Free Protein Expression Research in the United States?

“Government Initiatives and Increased Cell-Based Research in Academic Institutions”

Attribute	United States
Market Value (2024E)	US$ 154 Million
Growth Rate (2024 to 2034)	7.2% CAGR
Projected Value (2034F)	US$ 309 Million

In the United States, cell-based research is becoming more and more common in both academic institutions and the biotechnology sector. In recent years, several government initiatives have contributed to the growth of the market in the United States.

Presence of several key players who are continuously working on the cell-free protein expression synthesis process to develop different recombinant proteins used for pharmaceutical product production, protein-based drug delivery, antibodies, enzymes for disease treatment, etc. is a key cell-free protein expression market trend.

Why Does China Have the Potential to Be a Key Market in This Space?

“Growing Emphasis on Personalized Medicine Attracting Attention of Researchers”

Attribute	China
Market Value (2024E)	US$ 31 Million
Growth Rate (2024 to 2034)	8.6% CAGR
Projected Value (2034F)	US$ 70 Million

Creation of particular therapeutic proteins is frequently necessary for customized medicine. Examples of these include patient-specific antibodies and tailored cancer vaccinations. Personalized medicine is all about individualization, and cell-free protein expression technologies provide the ability to quickly manufacture tailored proteins. China is a possible market because of the rapid and efficient manufacturing of proteins made possible by cell-free protein expression, which also shortens the time required to develop customized therapies.

Category-wise Evaluation

Among various applications, the protein labeling segment is analyzed to expand at a CAGR of 8.5% from 2024 to 2034.

Why are E.coli-Based Systems Extensively Utilized?

“E.coli-Based Systems Facilitating Research on Interactions and Tolerability of By-Products”

Attribute	E.coli Cell Free
Segment Value (2024E)	US$ 180.4 Million
Growth Rate (2024 to 2034)	7.9% CAGR
Projected Value (2034F)	US$ 385 Million

Because of their increased protein output and affordability, E. Coli lysates are among the most useful and often used lysates. E. coli-based systems are used in recombinant technology to produce a range of biological medicines, including insulin. Investigation into the interactions and tolerability of by-products from E. coli-based systems has been made possible by continuous usage.

Which Expression Mode is Widely Employed by Researchers During Tests?

“Continuous Flow Expression Allowing Uninterrupted Synthesis of Cell-Free Protein Expression”

Attribute	Continuous Flow Expression
Segment Value (2024E)	US$ 233 Million
Growth Rate (2024 to 2034)	7.2% CAGR
Projected Value (2034F)	US$ 465.3 Million

The protein of interest and other byproducts may be continually filtered out without any interruptions while solutions are continuously fed into the reaction chamber thanks to continuous flow expression. Its appeal stems from the fact that this expression method makes it possible to synthesize cell-free protein expression continuously and uninterruptedly.

Market Landscape

To increase their market position, key players in the cell-free protein expression industry are utilizing a range of organic and inorganic tactics, including joint ventures, mergers and acquisitions, regional expansion, and strategic alliances, and adapting themselves to evolving market trends such as in vitro protein expression and recombinant proteins.

• The pharmaceutical discovery and development company 'CCM Bioscience' revealed CCM Protein Upregulation as its newest business unit in September 2023.
• VantAI, a significant player in the drug development space that uses artificial intelligence, announced in September 2023 the formation of its most recent 'Scientific Advisory Board' (SAB).
• Scientists Louis Brus, Moungi Bawendi, and Alexei Ekimov were awarded the Nobel Prize in Chemistry in October 2023 for their discovery of the synthesis of quantum dots, which brighten computer monitors and television screens that medical professionals use to identify cancers.

Fact.MR provides detailed information about the price points of key cell-free protein expression companies positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new cell-free protein expression market report.

Key Segments of Cell-Free Protein Expression Market Research

• By Product :

  • E.coli Cell-free Protein Expression Systems
  • Rabbit Reticulocytes Protein Expression Systems
  • Wheat Germ Cell-free Protein Expression Systems
  • Insect Cells Cell-free Protein Expression Systems
  • Mammalian Cell-free Protein Expression Systems

• By Application :

  • Enzyme Engineering
  • Protein Labelling
  • Protein-Protein Interaction
  • Protein Purification

• By Expression Mode :

  • Continuous Flow Expression
  • Batch Expression

• By End User :

  • Biotechnological Companies
  • Pharmaceutical Companies
  • Contract Research Organization
  • Academic and Research Institutes

• By Region :

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa